Gabriella Camboni

Maria Gabriella Camboni is a Partner in Sofinnova Biovelocita Strategy. She was co-founder and CEO of BiovelocITA, Italy's first accelerator dedicated to biotech, and the model for the Sofinnova Biovelocita Strategy.

As a Partner, Gabriella's mission is to work with universities, research organizations and investors to create companies from the most ground-breaking scientific ideas.

"Working with researchers to create new startups is personally very rewarding," she said, "because you're helping to move promising science into the real world, where patients benefit."

Earlier in her career, Gabriella was Chief Operations Officer of Ethical Oncology Science (EOS), a Sofinnova-backed startup devoted to translational research in oncology, which she co-founded with Silvano Spinelli in 2006. EOS was sold to Clovis in 2013.

Prior to this, Gabriella held various positions in the pharmaceutical industry, including Head of Clinical Oncology at Boehringer Mannheim Italy, Head of Development at Novuspharma (a spin-off of Boehringer Mannheim that she co-founded, which is now CTI BioPharma), and Head of Medical Affairs Europe at Novartis Oncology.

Gabriella obtained her MD from the University of Milan; she is a board-certified gastroenterologist and clinical pharmacologist.